Teladoc Health Earnings & Forecasts

Teladoc Health (TDOC) earnings history, EPS estimates, revenue forecasts and company guidance.

Earnings Per Share (Non-GAAP)

四半期利益の驚きの金額

会計四半期	報告日	実質EPS	推定EPS	驚き％
Q2	Jul 29, 2026	$-0.21	$-0.24	12.5 %
Q1	Apr 29, 2026	$-0.36	$-0.37	2.70 %
Q4	Feb 25, 2026	$-0.14	$-0.21	33.3 %
Q3	Oct 29, 2025	$-0.20	$-0.24	16.7 %

Quarterly Revenue (Billions)

四半期売上高の驚きの金額

会計四半期	報告日	実際の収益	推定収益	驚き％
Q2	Jul 29, 2026	$606.93M	$615.58M	-1.41 %
Q1	Apr 29, 2026	$613.85M	$610.93M	0.48 %
Q4	Feb 25, 2026	$642.27M	$634.76M	1.18 %
Q3	Oct 29, 2025	$626.44M	$630.93M	-0.71 %

Teladoc Health Guidance

Teladoc Health (TDOC) は、7 29, 2026 年に Q3 2026 のガイダンスを最後に発表しました。同社は 1 株当たり利益を $-0.3 - $-0.2 の範囲と予想し、コンセンサス EPS 予想は $-0.17 でした。Teladoc Health も、この期間の売上高を $569M - $609M の範囲と予想しました。

以前のガイダンスと比較して、Teladoc Healthは売上高予測を以前の範囲である引き下げから$2.36B - $2.45Bに引き上げました。

Teladoc Healthは、34から10 26, 2022の間に7 29, 2026ガイダンスの更新を発表しました。During this period, the company raised its outlook 7 times and lowered it 15 times, providing investors with insight into management's evolving expectations.

Recent Earnings Results

Metric	Q2 '26	Q1 '26	Q4 '25	Q3 '25
Earnings Per Share (Non-GAAP)
Estimate	$-0.24	$-0.37	$-0.21	$-0.24
Actual	$-0.21	$-0.36	$-0.14	$-0.20
Surprise	+12.5%	+2.70%	+33.3%	+16.7%
Revenue
Estimate	$615.6M	$610.9M	$634.8M	$630.9M
Actual	$606.9M	$613.8M	$642.3M	$626.4M
Surprise	-1.41%	+0.48%	+1.18%	-0.71%

Analyst Estimates — Forward PeriodsSource: Wall Street consensus

Metric	Q3 '26E	Q4 '26E	Q1 '27E	Q2 '27E
Earnings Per Share (Non-GAAP)
Consensus	$-0.21	$-0.11	$-0.24	$-0.20
Revenue
Consensus	$591.0M	$602.9M	—	—

More with Benzinga EdgeGet Access

Earnings & Guidance News

Why Teladoc Stock is Getting Crushed Wednesday After Hours

Teladoc stock is sinking Wednesday after the company reported Q2 results and updated guidance. Here are the key figures to know.

Chris Katje

PRO
Teladoc Health Sees Q3 GAAP EPS $(0.30)-$(0.20) vs $(0.18) Est; Sees Sales $569.000M-$609.000M vs $629.252M Est

Teladoc Health (NYSE:TDOC) is looking for Q3 GAAP EPS of $(0.30)-$(0.20) vs $(0.18) analyst estimate. sees sales of $569.000 million-$609.000 million vs $629.252 million analyst estimate.

Benzinga Newsdesk

PRO
Teladoc Health Raises FY2026 GAAP EPS Guidance from $(1.05)-$(0.75) to $(1.00)-$(0.75) vs $(0.92) Est; Lowers FY2026 Sales Guidance from $2.481B-$2.576B to $2.362B-$2.447B vs $2.508B Est

Teladoc Health (NYSE:TDOC) raises FY2026 GAAP EPS guidance from $(1.05)-$(0.75) to $(1.00)-$(0.75) vs $(0.92) analyst estimate. Lowers FY2026 sales outlook from $2.481 billion-$2.576 billion to $2.362 billion-$2.447

Benzinga Newsdesk

PRO
Teladoc Health Q2 EPS $(0.21) Beats $(0.25) Estimate, Sales $606.927M Miss $615.391M Estimate

Teladoc Health (NYSE:TDOC) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.25) by 16 percent. This is a 10.53 percent decrease over losses of $(0.19) per share from the

Benzinga Newsdesk

Teladoc Shares Fall After Q1 Earnings: What Investors Need To know

Teladoc stock is trading lower after reporting first-quarter financial results. Here are the highlights.

Chris Katje

PRO
Teladoc Health Narrows FY2026 GAAP EPS Guidance from $(1.10)-$(0.70) to $(1.05)-$(0.75) vs $(0.89) Est; Narrows FY2026 Sales Guidance from $2.470B-$2.587B to $2.481B-$2.576B vs $2.509B Est.

Teladoc Health (NYSE:TDOC) narrows FY2026 GAAP EPS guidance from $(1.10)-$(0.70) to $(1.05)-$(0.75) vs $(0.89) analyst estimate. Narrows FY2026 sales outlook from $2.470 billion-$2.587 billion to $2.481 billion-$2.576

Benzinga Newsdesk

Teladoc Health Inc